Axon Therapies Appoints Industry Veteran Brian Farley to Board of Directors

SANTA CLARA, Calif., Feb. 15, 2022 /PRNewswire/ -- Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced the appointment of Brian Farley to the company's Board of Directors. With three decades of experience leading medtech companies, Mr. Farley brings a track record of successfully developing and commercializing novel, market-shaping technologies. He joins the Axon board as the company builds momentum in its ongoing feasibility study REBALANCE-HF, which is evaluating the safety and efficacy of its novel Splanchnic Ablation for Volume Management (SAVM) procedure in heart failure patients with preserved ejection fraction (HFpEF).

Read more at prnewswire.com